• The chemical company project seemingly back on track
• The Chematur MoU converted into an agreement
• We keep our fair value of SEK 3.7 per share
  

Bioextrax reported Q1 2026 figures close to our estimates, with total revenues of KSEK 228 and an EBIT of MSEK -4.3. Cost control remains critical as the company works towards cash flow neutrality, and it left the quarter with a cash balance of MSEK 11.6. On the commercial side, the Chematur Engineering MoU has now converted into an agreement related to a two-phase project with a potential value of MEUR 3.4 for Bioextrax. Negotiations with the chemical company also appear to have resumed after a breakthrough in the patent landscape, with CEO Edvard Hall expressing hope for a binding contract by the end of June. We keep our fair value unchanged at SEK 3.7 per share.

Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Läs mer på MFN